Visualizing and Modulating Mitophagy for Therapeutic Studies of Neurodegeneration.


Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
28 05 2020
Historique:
received: 29 10 2019
revised: 06 03 2020
accepted: 15 04 2020
pubmed: 22 5 2020
medline: 17 12 2020
entrez: 22 5 2020
Statut: ppublish

Résumé

Dysfunctional mitochondria accumulate in many human diseases. Accordingly, mitophagy, which removes these mitochondria through lysosomal degradation, is attracting broad attention. Due to uncertainties in the operational principles of conventional mitophagy probes, however, the specificity and quantitativeness of their readouts are disputable. Thorough investigation of the behaviors and fates of fluorescent proteins inside and outside lysosomes enabled us to develop an indicator for mitophagy, mito-SRAI. Through strict control of its mitochondrial targeting, we were able to monitor mitophagy in fixed biological samples more reproducibly than before. Large-scale image-based high-throughput screening led to the discovery of a hit compound that induces selective mitophagy of damaged mitochondria. In a mouse model of Parkinsons disease, we found that dopaminergic neurons selectively failed to execute mitophagy that promoted their survival within lesions. These results show that mito-SRAI is an essential tool for quantitative studies of mitochondrial quality control.

Identifiants

pubmed: 32437660
pii: S0092-8674(20)30488-8
doi: 10.1016/j.cell.2020.04.025
pii:
doi:

Substances chimiques

Fluorescent Dyes 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1176-1187.e16

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests H. Katayama and A.M. are inventors on patent application PCT/JP2016/068189 submitted by RIKEN that covers the creation and use of SRAI/mito-SRAI.

Auteurs

Hiroyuki Katayama (H)

Laboratory for Cell Function Dynamics, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako-City, Saitama 351-0198, Japan.

Hiroshi Hama (H)

Laboratory for Cell Function Dynamics, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako-City, Saitama 351-0198, Japan.

Koji Nagasawa (K)

Innovative Biology Laboratories, Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.

Hiroshi Kurokawa (H)

Laboratory for Cell Function Dynamics, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako-City, Saitama 351-0198, Japan.

Mayu Sugiyama (M)

Laboratory for Cell Function Dynamics, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako-City, Saitama 351-0198, Japan.

Ryoko Ando (R)

Laboratory for Cell Function Dynamics, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako-City, Saitama 351-0198, Japan.

Masaaki Funata (M)

Innovative Biology Laboratories, Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.

Nobuyo Yoshida (N)

Cardiovascular and Metabolic Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.

Misaki Homma (M)

Drug Discovery Chemistry Laboratories, Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.

Takanori Nishimura (T)

Innovative Biology Laboratories, Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.

Megumu Takahashi (M)

Department of Cell Biology and Neuroscience, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan.

Yoko Ishida (Y)

Department of Cell Biology and Neuroscience, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan.

Hiroyuki Hioki (H)

Department of Cell Biology and Neuroscience, Graduate School of Medicine, Juntendo University, Tokyo 113-8421, Japan.

Yoshiyuki Tsujihata (Y)

Innovative Biology Laboratories, Neuroscience Drug Discovery Unit, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan. Electronic address: yoshiyuki.tsujihata@takeda.com.

Atsushi Miyawaki (A)

Laboratory for Cell Function Dynamics, RIKEN Center for Brain Science, 2-1 Hirosawa, Wako-City, Saitama 351-0198, Japan; Biotechnological Optics Research Team, Center for Advanced Photonics, RIKEN, 2-1 Hirosawa, Wako-City, Saitama 351-0198, Japan. Electronic address: atsushi.miyawaki@riken.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH